Neurology and Neurosurgery

17-30 of 30

• 

  RestartResume

  Ocular to Generalized MG: How and Why the Disease Evolves

  RestartResume

  Ocular to Generalized MG: How and Why the Disease Evolves

  MinuteCE®

  Ocular to Generalized MG: How and Why the Disease Evolves

  Vera Bril, MD; Hans Katzberg, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credit

• 

  RestartResume

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  RestartResume

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  MinuteCE®

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  RestartResume

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  MinuteCE®

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  RestartResume

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  MinuteCE®

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  RestartResume

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  MinuteCE®

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  RestartResume

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  MinuteCE®

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Diagnostic Advances in gMG: Effective Tools and Techniques

  RestartResume

  Diagnostic Advances in gMG: Effective Tools and Techniques

  MinuteCE®

  Diagnostic Advances in gMG: Effective Tools and Techniques

  Vera Bril, MD; Hans Katzberg, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credit

• 

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  CME/CE

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  Vera Bril, MD; Jonathan Strober, MD

  0.75 credits

  • 

    

    Vera Bril, MD

  • 

    

    Jonathan Strober, MD

  0.75 credits

• 

  RestartResume

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  RestartResume

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  MinuteCE®

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  MinuteCE®

  Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 credit 10 episodes

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  • 

    

    Hans Katzberg, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  RestartResume

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  MinuteCE®

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  Vera Bril, MD; Hans Katzberg, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credit

• 

  RestartResume

  The Safety of Sodium Oxybate in Treating Narcolepsy

  RestartResume

  The Safety of Sodium Oxybate in Treating Narcolepsy

  CME/CE

  The Safety of Sodium Oxybate in Treating Narcolepsy

  Clete A. Kushida, MD, PhD; Sally Ibrahim, MD, FAAP

  0.50 credits

  • 

    

    Clete A. Kushida, MD, PhD

  • 

    

    Sally Ibrahim, MD, FAAP

  0.50 credits

• 

  RestartResume

  Duchenne Muscular Dystrophy: Differentiating Advances in Treatment 

  RestartResume

  Duchenne Muscular Dystrophy: Differentiating Advances in Treatment 

  CME/CE

  Duchenne Muscular Dystrophy: Differentiating Advances in Treatment 

  Omer Abdul Hamid, MD; Nancy Kuntz, MD

  0.25 credits

  • 

    

    Omer Abdul Hamid, MD

  • 

    

    Nancy Kuntz, MD

  • 

    

    Migvis Monduy, MD

  0.25 credits

• 

  RestartResume

  Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome

  RestartResume

  Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome

  CME/CE

  Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome

  Nilika Singhal, MD; M. Scott Perry, MD

  • 

    

    Nilika Singhal, MD

  • 

    

    M. Scott Perry, MD

  • 

    

    Elizabeth Anne Thiele, MD, PhD

• Previous
• 1
• 2
• Next